• 1
    Sutula TP, Hagen J, Pitkanen A. Do epileptic seizures damage the brain? Curr Opin Neurol 2003;16: 18995.
  • 2
    Tarulli A, Devinsky O, Alper K. Progression of postictal to interictal psychosis. Epilepsia 2001;42: 146871.
  • 3
    Devinsky O, Najjar S. Evidence against the existence of a temporal lobe epilepsy personality syndrome. Neurology. 1999;53(suppl 2):S1325.
  • 4
    Wirrell EC, Camfield CS, Camfield PR, Gordon KE, Dooley JM. Long-term prognosis of typical childhood absence epilepsy: remission or progression to juvenile myoclonic epilepsy. Neurology 1996;47: 9128.
  • 5
    Yung AW, Park YD, Cohen MJ, Garrison TN. Cognitive and behavioral problems in children with centrotemporal spikes. Pediatr Neurol 2000;23: 3915.
  • 6
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Fourth edition. Text revision. Washington , DC : American Psychiatric Press, 2000.
  • 7
    Romberg H. A manual of the nervous diseases of manSievekingEH, trans-ed. London , England : Sydenham Society , 1853: 203.
  • 8
    Blake RV, Wroe SJ, Breen EK, McCarthy RA. Accelerated forgetting in patients with epilepsy: evidence for an impairment in memory consolidation. Brain 2000: 123: 47283.
  • 9
    Pulliainen V, Kuikka P, Jokelainen M. Motor and cognitive functions in newly diagnosed adult seizure patients before antiepileptic medication. Acta Neurol Scand 2000;101: 738.
  • 10
    Aarts JHP, Bimmin CD, Smit AD, Wilkins AJ. Selective cognitive impairment during focal and generalized epileptiform EEG activity. Brain 1984;107: 293308.
  • 11
    Smith DB. Anticonvulsants, seizures and performance. In: TrimbleMR, ReynoldsEH, eds. Epilepsy, behaviour and cognitive function. New York : Wiley, 1988: 6778.
  • 12
    Devinsky O. Cognitive and behavioral effects of antiepileptic drugs. Epilepsia 1995: 36(suppl 2):S4665.
  • 13
    Drane DL, Meador KJ. Epilepsy, anticonvulsant drugs and cognition. Baillieres Clin Neurol 1996: 5: 87785.
  • 14
    Henry TR. Functional neuroimaging with positron emission tomography. Epilepsia 1996: 37: 114154.
  • 15
    Lee S, Sziklas V, Andermann F, et al. The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia 2003;44: 33947.
  • 16
    Devinsky O. Cognitive and behavioral effects of antiepileptic drugs. Epilepsia 1995;36(suppl 2):S4665.
  • 17
    Shulman MB, Barr W. Treatment of memory disorders in epilepsy. Epilepsy Behav 2002;3(5S):304.
  • 18
    Fisher RS, Bortz JJ, Blum DE, Duncan B, Burke H. A pilot study of donepezil for memory problems in epilepsy. Epilepsy Behav 2001;2: 3304.
  • 19
    McKenna DJ, Jones K, Hughes K. Efficacy, safety, and use of ginkgo biloba in clinical and preclinical applications. Altern Ther Health Med 2001: 27: 7090.
  • 20
    Van Dongen MC, Van Rossum E, Kessels AG, Sielhorst HJ, Knipschild PG. The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial. J Am Geriatr Soc 2000;48: 118394.
  • 21
    Moulton PL, Boyko LN, Fitzpatrick JL, Petros TV. The effect of Ginkgo biloba on memory in healthy male volunteers. Physiol Behav 2001;73: 65965.
  • 22
    Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm 2000;57: 12217.
  • 23
    Dunn DW, Austin JK, Harezlak J, Ambrosius WT. ADHD and epilepsy in childhood. Dev Med Child Neurol 2003;45: 504.
  • 24
    Gucuyener K, Erdemoglu AK, Senol S, Serdaroglu A, Soysal S, Kockar AI. Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. J Child Neurol 2003;18: 10912.
  • 25
    Hemmer SA, Pasternak JF, Zecker SG, Trommer BL. Stimulant therapy and seizure risk in children with ADHD. Pediatr Neurol 2001;24: 99102.
  • 26
    Gross-Tsur V, Manor O, Van Der Meere J, Joseph A, Shalev RS. Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective? J Pediatr 1997;130: 6704.
  • 27
    Frucht MM, Quigg M, Schwaner C, Fountain NB. Distribution of seizure precipitants among epilepsy syndromes. Epilepsia 2000;41: 15349.
  • 28
    Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 2002;72: 17983.
  • 29
    Mendez MF, Cummings JL, Benson DF. Depression in epilepsy: significance and phenomenology. Arch Neurol 1986;43: 76670.
  • 30
    Lambert MV, Robertson MM. Depression in epilepsy: etiology, phenomenology, and treatment. Epilepsia 1999;40(suppl 10):S2147.
  • 31
    Matthews WS, Barbaras G. Suicide and epilepsy: a review of the literature. Psychosomatics 1981;22: 51524.
  • 32
    Hermann BP, Whitman S. Psychosocial predictors of interictal depression. J Epilepsy 1989;2: 2317.
  • 33
    Bromfield EB, Altshuler L, Leiderman DB, Balish M, Ketter TA, Devinsky O. Cerebral metabolism and depression in patients with complex partial seizures. Arch Neurol 1992: 49: 61723.
  • 34
    Kanner AM, Nieto JC. Depressive disorders in epilepsy. Neurology 1999;53(suppl 2):S2632.
  • 35
    Boylan L, Flint LA, Labovitz DL, Jackson SC, Starner K, Devinsky O. Depression but not seizure frequency predicts quality of life in treatment resistant epilepsy. Neurology 2004;62: 25861.
  • 36
    Ojemann LM, Baugh-Bookman C, Dudley DL. Effect of psychotropic medications on seizure control in patients with epilepsy. Neurology 1987;37: 15257.
  • 37
    Gross A, Devinsky O, Westbrook LE, Wharton AH, Alper K. Psychotropic medication use in patients with epilepsy: effect on seizure frequency. J Neuropsychiatry Clin Neurosci 2000;12: 45864.
  • 38
    Wiart L, Petit H, Joseph PA, Mazaux JM, Barat M. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke 2000;31: 182932.
  • 39
    Perini G, Mendius R. Depression and anxiety in complex partial seizures. J Nerv Ment Dis 1984;172: 28790.
  • 40
    Altshuler LL, Devinsky O, Post RM, Theodore W. Depression, anxiety and temporal lobe epilepsy: laterality of focus and symptomatology. Arch Neurol 1990;47: 2848.
  • 41
    Vazquez B, Devinsky O, Luciano D, Alper K, Perrine K. Juvenile myoclonic epilepsy: clinical features and factors related to misdiagnosis. J Epilepsy 1993;6: 2338.
  • 42
    Cutting S, Lauchheimer A, Barr W, Devinsky O. Adult-onset idiopathic generalized epilepsy: clinical and behavioral features. Epilepsia 2001;42: 13958.
  • 43
    Slater E, Beard AW. The schizophrenia-like psychoses of epilepsy. Br J Psychiatry 1963;109: 95150.
  • 44
    Whitman S, Hermann BP, Gordon A. Psychopathology in epilepsy: how great is the risk? Biol Psychiatry 1984;19: 2136.
  • 45
    Trimble MR. The psychoses of epilepsy. New York : Raven Press, 1991.
  • 46
    Mendez MF, Grau R, Doss RC, Taylor JL. Schizophrenia in epilepsy: seizure and psychosis variables. Neurology 1993;43: 10737.
  • 47
    Gessa GL, Devoto P, Diana M, Flore G, Melis M, Pistis M. Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex. Neuropsychopharmacology 2000;22: 6429.
  • 48
    Strange PG. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev 2001;53: 11933.
  • 49
    Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 1988;8(suppl):52S56S.
  • 50
    Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 1992;18: 70115.
  • 51
    DeLeon OA. Antiepileptic drugs for the acute and maintenance treatment of bipolar disorder. Harv Rev Psychiatry 2001;9: 20922.
  • 52
    Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Psychopharmacol 1999;19: 3418.
  • 53
    Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000;20: 60714.
  • 54
    Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group . Bipolar Disord 2000;2: 24955.
  • 55
    Martin R, Kuzniecky R, Ho S, et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 1999;52: 3217.
  • 56
    Besag FM. Behavioural effects of the new anticonvulsants. Drug Saf 2001;24: 51336.
  • 57
    Crawford P. An audit of topiramate use in a general neurology clinic. Seizure 1998;7: 20711.
  • 58
    Stephen LJ, Sills GJ, Brodie MJ. Topiramate in refractory epilepsy: a prospective observational study. Epilepsia 2000;41: 97780.
  • 59
    Ketter TA, Post RM, Theodore WH. Positive and negative psychotropic effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999;53(suppl 1):S52S66.
  • 60
    Uvebrant P, Bauziene R. Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatrics 1994;25: 2849.